Last updated: September 27, 2026
PENLAC is the former U.S. brand for ciclopirox 8% topical solution, a prescription nail lacquer used to treat mild-to-moderate toenail fungal infection. Its commercial trajectory has shifted from branded prescription sales to a low-price generic market. The original U.S. regulatory and patent protections have expired, no meaningful branded exclusivity remains, and standalone PENLAC revenue is not publicly reported.
What is PENLAC and what drug does it contain?
PENLAC contains ciclopirox, an antifungal agent formulated as an 8% topical solution applied to infected nails. The product was approved by the U.S. Food and Drug Administration for mild-to-moderate onychomycosis involving fingernails and toenails without lunula involvement. Treatment requires daily application and periodic removal of the accumulated lacquer layer.[1]
| Attribute |
PENLAC |
| Active ingredient |
Ciclopirox |
| Strength |
8% |
| Dosage form |
Topical nail lacquer/solution |
| Original U.S. sponsor |
Hoechst Marion Roussel, later associated with Sanofi |
| FDA application |
NDA 020748 |
| Primary indication |
Mild-to-moderate toenail and fingernail onychomycosis |
| U.S. approval |
1999 |
| Prescription status |
Prescription drug |
| Current market position |
Generic-dominated |
| U.S. biosimilar exposure |
None |
| Primary competitors |
Generic ciclopirox, Jublia, Kerydin, tavaborole, oral terbinafine, OTC products |
PENLAC was designed for patients with relatively limited nail disease. It is less suitable for extensive infection, matrix involvement, or cases requiring rapid clearance. The product’s clinical positioning was constrained by modest cure rates, long treatment duration, and the practical burden of daily application.[1]
When did PENLAC lose exclusivity?
PENLAC lost meaningful market exclusivity after the expiration of its original patent and regulatory protections. The product has no current U.S. orphan-drug exclusivity, pediatric exclusivity, or other FDA exclusivity that would restrict generic competition.
The commercial exclusivity timeline is broadly as follows:
| Milestone |
Approximate timing |
Market effect |
| FDA approval |
1999 |
Launch of branded prescription product |
| Original patent period |
Expired during the 2000s |
Patent barrier removed |
| Generic approvals |
Primarily after patent protection ended |
Price competition increased |
| Brand erosion |
2010s |
Prescribing shifted toward generic ciclopirox and newer branded agents |
| Current position |
2020s |
Low-price, generic-led category |
The exact patent landscape depends on the relevant formulation, manufacturing process, and jurisdiction. The original U.S. protection associated with the PENLAC product is no longer an effective barrier to generic entry. FDA records and the Orange Book list the product and its approved generic equivalents, but they do not provide a current exclusivity barrier comparable to an active patent-protected specialty drug.[2][3]
What is the Orange Book status of PENLAC?
PENLAC is associated with FDA’s approved drug database and the Orange Book framework for prescription products. The relevant reference product is ciclopirox topical solution 8%, NDA 020748.
The regulatory position is commercially weak:
- No current market exclusivity prevents generic approval.
- Generic ciclopirox 8% topical solutions can compete through the abbreviated new drug application pathway.
- The product is not a biologic and does not receive protection under the Biologics Price Competition and Innovation Act.
- Biosimilar litigation and interchangeability issues do not apply.
- Any remaining patent listings would need to be assessed against the current Orange Book entry and patent certifications for specific generic applications.
The Orange Book does not determine actual pharmacy availability. A product can remain approved while being commercially discontinued, intermittently supplied, or replaced by generic products. That distinction matters for PENLAC because brand-level availability and brand-level sales are materially different from the continued regulatory existence of the product.[2]
How large is the PENLAC market?
No reliable public source reports standalone PENLAC revenue. Financial disclosures from large pharmaceutical companies generally aggregate topical dermatology products, prescription antifungals, or legacy products rather than reporting PENLAC separately.
The addressable market is the U.S. onychomycosis treatment market, which includes:
- Generic ciclopirox;
- Branded topical products such as Jublia;
- Tavaborole products such as Kerydin and generic or authorized-generic alternatives where available;
- Oral terbinafine;
- Itraconazole;
- Over-the-counter antifungal products;
- Compounded or nonprescription nail treatments.
PENLAC’s revenue trajectory is therefore best characterized as a decline from branded prescription revenue to a fragmented generic market.
| Period |
Revenue trajectory |
Main commercial driver |
| 1999-2005 |
Growth from new-product launch |
Prescription adoption and limited competition |
| 2006-2012 |
Decline begins |
Patent expiry and generic entry |
| 2013-2018 |
Accelerated erosion |
New branded topical products and generic substitution |
| 2019-2023 |
Low-value, generic-led market |
Discounting, formulary pressure, limited differentiation |
| 2024 onward |
Mature and largely commoditized |
Low prices, pharmacy access, adherence limitations |
The product’s economic value is now concentrated in manufacturing efficiency, pharmacy distribution, and generic approval status rather than brand equity.
What is driving demand for ciclopirox and PENLAC?
Demand is supported by the high prevalence of fungal nail disease, but treatment demand does not translate directly into branded PENLAC revenue.
Disease prevalence
Onychomycosis affects a significant share of adults, with prevalence increasing with age, diabetes, peripheral vascular disease, and immune compromise. Many patients do not seek treatment, and some use OTC products or receive no therapy. This creates a large clinical market but a smaller prescription market.[4]
Treatment limitations
Ciclopirox 8% has several commercial disadvantages:
- Daily application is required.
- The nail must be treated for an extended period, often close to 48 weeks.
- The lacquer must be removed periodically.
- Clinical response is slow because the nail must grow out.
- Efficacy is generally lower than that of oral terbinafine in appropriate patients.
- Patients with extensive disease may require systemic therapy.
These factors reduce persistence and refill frequency. A patient who does not observe visible improvement may discontinue therapy before completing the full treatment course.
Safety and patient selection
Ciclopirox has an advantage in patients who cannot use oral terbinafine because of hepatic risk, drug interactions, monitoring requirements, or preference for local treatment. Its topical route also supports use in patients seeking to avoid systemic exposure.
The tradeoff is lower efficacy and a longer treatment period. The product therefore occupies a secondary position in treatment algorithms rather than functioning as the default therapy for all onychomycosis patients.
How does PENLAC compare with Jublia, Kerydin, and oral terbinafine?
PENLAC competes on price and topical tolerability, not on rapid clearance or convenience.
| Product |
Ingredient |
Route |
Commercial position |
Main advantage |
Main limitation |
| PENLAC/generic |
Ciclopirox 8% |
Topical |
Low-cost generic |
Low acquisition cost; no systemic exposure |
Daily use and modest efficacy |
| Jublia |
Efinaconazole 10% |
Topical |
Branded specialty product |
Easier application; no lacquer removal |
High branded cost |
| Kerydin |
Tavaborole 5% |
Topical |
Branded topical product |
Penetration-oriented formulation |
Cost and variable access |
| Lamisil/generic |
Terbinafine |
Oral |
Standard systemic therapy |
Higher efficacy and shorter course |
Hepatic and interaction concerns |
| OTC antifungals |
Various |
Topical |
Consumer market |
Easy access and low upfront cost |
Limited evidence for nail penetration |
Jublia and Kerydin were introduced with premium pricing and differentiated delivery claims. Their commercial opportunity depended on obtaining payer coverage despite the availability of generic ciclopirox and oral terbinafine. PENLAC remains relevant when cost, topical administration, or avoidance of systemic therapy is prioritized.
What patents protect PENLAC today?
The current PENLAC patent position is weak. The original product patents and associated exclusivity periods have expired, allowing generic ciclopirox 8% topical solutions to enter the U.S. market.
Potentially relevant intellectual-property categories include:
- Active ingredient patents. These are expired and do not restrict current ciclopirox use.
- Topical nail-lacquer formulation patents. Original formulation protection associated with the branded product has expired or is no longer a practical barrier to generic competition.
- Manufacturing-process patents. These could affect particular production methods, but they do not prevent a generic manufacturer from using a non-infringing process.
- Method-of-use patents. No current broad method-of-use protection appears to create meaningful exclusivity for standard ciclopirox treatment of onychomycosis.
- Device or applicator patents. Any surviving claims would have a narrower commercial effect and would not restore brand-level exclusivity for the active ingredient.
The absence of a strong current patent estate means that PENLAC’s competitive position depends on regulatory approval, product quality, supply reliability, and contracting rather than litigation leverage.
Are there Paragraph IV challenges to PENLAC?
Paragraph IV litigation is not a current commercial driver for PENLAC. Paragraph IV certifications are most consequential when a branded product has valuable remaining patent life and substantial revenue at risk. PENLAC no longer fits that profile.
Generic applicants may have relied on patent certifications during the original generic-entry period, but the relevant disputes are historical rather than active drivers of present market access. Current generic competition is consistent with the product’s expired exclusivity position.
No active, material Paragraph IV dispute is required for generic ciclopirox to remain commercially available once the relevant listed patents have expired or ceased to block approval.
Which companies compete in the PENLAC market?
The market is fragmented across generic manufacturers, branded topical developers, oral antifungal suppliers, and pharmacy distributors. Generic availability can vary by national drug code, wholesaler inventory, and pharmacy contracting.
Competitive groups include:
- Generic manufacturers selling ciclopirox 8% topical solution;
- Bausch Health and associated dermatology businesses, where legacy branded or generic dermatology products are commercialized;
- Ortho Dermatologics and other companies associated with branded topical antifungal products;
- Pharmaceutical companies selling efinaconazole and tavaborole;
- Manufacturers of generic terbinafine and itraconazole;
- OTC consumer-health companies.
The relevant competitive question is not whether PENLAC can defend premium pricing. It cannot. The question is whether a supplier can maintain reliable generic distribution at acceptable manufacturing margins.
What are the manufacturing and supply-chain barriers?
Manufacturing barriers are moderate rather than high. Ciclopirox is a small-molecule active ingredient, and the dosage form is a topical solution rather than a complex biologic or sterile injectable.
Potential barriers include:
- Consistent control of solvent composition;
- Viscosity and film-forming properties;
- Uniform drug content;
- Container-closure compatibility;
- Applicator performance;
- Stability over the labeled shelf life;
- Microbial-control requirements;
- Packaging and labeling compliance.
These requirements can create quality or supply problems, but they do not produce the same barriers seen with inhaled products, modified-release drugs, biologics, or complex injectables.
The greatest commercial risk is likely supply interruption rather than patent exclusion. A manufacturer with an approved ANDA, reliable API sourcing, and strong wholesaler relationships can compete without owning the former PENLAC brand.
What is the financial trajectory for PENLAC?
PENLAC’s financial trajectory is structurally downward at the brand level and stable-to-low-growth at the generic ingredient level.
Brand revenue
Brand revenue has likely declined sharply from its post-launch period because:
- Generic substitutes are available;
- Payers encourage substitution;
- Newer topical drugs offer differentiated positioning;
- Physicians can prescribe oral terbinafine at low cost;
- The product requires prolonged adherence;
- The brand has limited promotional value.
No public evidence supports treating PENLAC as a material standalone revenue contributor for a major pharmaceutical company today.
Generic revenue
Generic ciclopirox can generate recurring but modest revenue. Margin performance depends on:
- Number of approved suppliers;
- Contract pricing;
- Pharmacy benefit manager reimbursement;
- API costs;
- Manufacturing scale;
- Shortages or discontinuations among competitors;
- Dispensing volume relative to fixed regulatory costs.
Generic revenue can increase temporarily during supply disruption, but long-term pricing typically declines as additional suppliers enter.
Investor relevance
PENLAC is unlikely to affect the valuation of a diversified pharmaceutical company except as a minor legacy product or part of a broader dermatology portfolio. The asset could have value for a specialty-generic company seeking:
- An approved topical ANDA;
- Established prescribing history;
- Low clinical development risk;
- A product with relatively simple manufacturing;
- Cross-selling potential into dermatology.
The asset is unlikely to support premium licensing economics unless paired with a broader portfolio, manufacturing advantage, or geographic rights.
What generic launch scenarios exist for PENLAC?
Three scenarios are commercially plausible.
Base case: continued generic commoditization
Multiple suppliers maintain access, prices remain low, and brand PENLAC has little or no direct economic relevance. This is the most likely scenario.
Upside case: supply consolidation
If competing manufacturers discontinue the product or face quality problems, remaining suppliers could obtain temporary pricing improvement. The increase would be volume- and supply-driven rather than patent-driven.
Downside case: product withdrawal
If reimbursement falls below manufacturing and compliance costs, manufacturers may discontinue low-volume presentations. Patients would shift to other generic suppliers, branded topical products, oral antifungals, or OTC alternatives.
How strong is the PENLAC patent estate?
PENLAC has a weak current patent estate.
| Factor |
Assessment |
| Active composition-of-matter protection |
None of practical relevance |
| Current FDA exclusivity |
None of material relevance |
| Formulation protection |
Expired or commercially narrow |
| Method-of-use protection |
No broad effective barrier identified |
| Generic entry risk |
High |
| Biosimilar risk |
Not applicable |
| Litigation leverage |
Low |
| Manufacturing barrier |
Moderate |
| Brand pricing power |
Low |
| Licensing value |
Limited unless bundled |
The product’s defensibility is regulatory and operational, not patent-based.
Key Takeaways
- PENLAC is ciclopirox 8% topical solution for mild-to-moderate onychomycosis.
- The original brand has lost meaningful U.S. exclusivity.
- Generic ciclopirox is the dominant economic model.
- No biosimilar risk applies because PENLAC is a small-molecule drug.
- Paragraph IV litigation is not a material current market issue.
- Brand-level revenue is not publicly reported and is likely limited.
- Generic revenue depends on manufacturing cost, supply reliability, and reimbursement.
- Jublia, Kerydin, oral terbinafine, and OTC products define the competitive environment.
- The patent estate is weak; the principal barriers are regulatory compliance, quality control, and distribution.
- PENLAC has limited standalone licensing or valuation potential unless acquired as part of a broader generic dermatology portfolio.
FAQs
Is PENLAC still sold in the United States?
Ciclopirox 8% topical solution remains available through generic products, while branded PENLAC availability may vary by manufacturer, wholesaler, and pharmacy channel.
Is PENLAC stronger than terbinafine?
No. Oral terbinafine generally has higher efficacy for appropriate patients, but ciclopirox avoids systemic exposure and may be used when oral therapy is unsuitable.
Does PENLAC have an active U.S. patent?
The original patent and exclusivity protections associated with PENLAC no longer provide a meaningful barrier to generic entry.
Can a company launch a generic version of PENLAC?
Yes. A manufacturer can seek approval for a ciclopirox 8% topical solution through the ANDA pathway, subject to FDA requirements and any applicable listed-patent certifications.
Is PENLAC a valuable licensing asset?
As a standalone brand, PENLAC has limited licensing value. Its potential value is greater as an approved generic, a regional dermatology product, or part of a portfolio with manufacturing and distribution synergies.
References
- U.S. Food and Drug Administration. (1999). PENLAC nail lacquer: Ciclopirox topical solution 8% prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, NDA 020748.
- Lipner, S. R., & Scher, R. K. (2019). Onychomycosis: Clinical overview and diagnosis. Journal of the American Academy of Dermatology, 80(4), 835-851.
